Tenpoint Therapeutics has developed a platform that can be used to replace cells damaged with age or disease. This technology aims to make vision loss reversible. The startup established in London with operational headquarters in Allschwil at the Switzerland Innovation Park Basel Area has now announced in a press release that it will start operations with a series A round of financing amounting to 70 million US dollars. Basel Area Business & Innovation supported Tenpoint with its settlement in Allschwil  in the canton of Basel-Landschaft.

The biotech company will now develop cell-based therapies and perform in-vivo cell reprogramming. This makes healthy cells available to replace cells that can no longer function. Tenpoint’s CEO Eddy Anglade stated in the press release that most cases of vision loss are due to damaged or missing tissue, adding that this is why “cell-based therapeutics represent an ideal modality for degenerative ocular diseases.” Tenpoint focuses on addressing the causes of vision loss.

All seed investors that had previously enabled the company to be set up were involved in the funding round. Additionally, a new investor was brought on board in the form of British Patient Capital. Chair of the Board David Guyer commented: “Tenpoint has great potential to lead ophthalmology into a new era, which will fully replace cells lost to degenerative conditions rather than merely endeavoring to slow the processes that drive vision loss.”